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INTRODUCTION
The optimal strategy for autologous bone marro w
transplantation (ABMT) for patients with acute myeloid
leukemia (AML) in first remission is not well defined.
Because ABMT relies primarily on the efficacy of the
p reparative regimen in the absence of a graft-versus-
leukemia effect, we studied an intensive regimen for autolo-
gous transplantation combining busulfan with high-dose
etoposide. Long-term follow-up of a small, primarily single-
center experience using this intensive regimen combined
with 4-hydro p e roxycyclophosphamide (4HC)-purged bone
m a rrow rescue suggested that the intensive regimen may
improve results, with long-term disease-free survival (DFS)
of 70% in 50 first-remission patients [1,2]. However,
although the treatment-related mortality rate was low (4%),
delayed engraftment, prolonged hospitalization, and severe
nonhematologic toxicity limited the broad application of
this treatment approach.
We modified our approach to autologous transplanta-
tion to allow the more widespread use of the intensive
busulfan-etoposide preparative regimen. We used periph-
eral blood stem cells rather than bone marro w, basing the
decision on the hypothesis that more rapid engraftment
would reduce the overall toxicity of the transplantation re g-
imen. Previous data have suggested that ABMT using
u n p u rged bone marrow directly after induction chemo-
therapy led to an unacceptably high rate of relapse [3]. We
t h e re f o re gave a single course of moderately intensive
p o s t remission therapy to achieve further cytoreduction of
the leukemia and to take advantage of a possible in vivo
p u rging effect, collecting peripheral blood stem cells during
the re c o v e ry phase from this chemotherapy [4]. Because
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ABSTRACT
We studied the feasibility, toxicity, and efficacy of a 2-step approach to autologous stem cell transplantation for
patients with acute myeloid leukemia in first remission. Step 1 consisted of consolidation chemotherapy including
cytarabine 2000 mg/m2 twice daily for 4 days concurrent with etoposide 40 mg/kg by continuous infusion over 4 d a y s .
During the re c o v e ry from this chemotherapy, peripheral blood stem cells were collected under granulocyte colony-
stimulating factor stimulation. Step 2, autologous stem cell transplantation, involved the preparative regimen of
busulfan 16 mg/kg followed by etoposide 60 mg/kg and reinfusion of unpurged peripheral blood stem cells. A total
of 128 patients were treated. During step 1, there was 1 tre a t m e n t - related death. A median CD34+ cell dose of
14 (×1 06/kg) was collected in 3 aphereses. Ten patients suff e red relapse before transplantation, and 117 patients
(91%) proceeded to transplantation. During step 2, there were 2 tre a t m e n t - related deaths, and 35 patients subse-
quently suff e red relapse. With median follow-up of 30 months, 5-year disease-free survival for all patients entere d
in the study is projected to be 55%. By cytogenetic risk group, 5-year disease-free survival is 73% for favorable-risk
patients, 51% for intermediate-risk patients, and 0% for poor-risk patients. We conclude that this 2-step appro a c h
to autologous transplantation produces excellent stem cell yields and allows a high percentage of patients to re c e i v e
the intended therapy. Pre l i m i n a ry efficacy analysis is very encouraging, with outcomes that appear superior to those
of conventional chemotherapy.
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our goal was to maximize the percentage of patients able to
p roceed to transplantation, the consolidation chemotherapy
was developed as a compromise between giving intensive
enough treatment to avoid a large number of early re l a p s e s
and avoiding excessive toxicity  that would result in
d ropouts from the treatment pro g r a m .
We report the success of this strategy in achieving excel-
lent peripheral blood stem cell mobilization with rapid
engraftment and decreased toxicity and enabling a high per-
centage of patients to undergo transplantation. The prelimi-
n a ry outcome results suggest that this treatment strategy
may be efficacious as well as feasible.
METHODS
Patient Selection
Patients entered this study from 6 centers from May
1993 to November 1998. All patients gave written informed
consent in accord with each institution’s committee on
human research. Eligible patients were over age 16 and, ini-
t i a l l y, up to age 60. In June 1994, based on the acceptable
toxicity profile of the treatment, patients up to age 70 were
eligible to be in the study. All patients were required to be in
first  remission of de novo AML. Patients with prior
myelodysplasia, myeloproliferative disease, or chemo-
therapy-related leukemia were excluded.
Complete remission was defined as normal bone
m a rrow morphology with fewer than 5% blasts, re s o l u-
tion of p reviously abnormal cytogenetics, no evidence of
ex t r a m e d u l l a ry leukemia, absolute neutrophil count (ANC)
≥1 5 0 0 /µL, and platelets ≥1 4 0 , 0 0 0 /µL. Before entry into
the study, patients must have been in complete re m i s s i o n
for at least 30 days but less than 6 months. We re q u i re d
adequate organ function, with bilirubin ,1.5 mg/dL,
alkaline phosphates and aspartate transaminase less than
twice the upper limit of normal, creatinine ,2.0 mg/dL,
c a rdiac ejection fraction ≥0.40, and diffusion capacity of
carbon monoxide ≥50%. Patients receiving pre v i o u s
p o s t re m i ss i o n high-dose cytarabine (ara-C), defined as
m o re than 4 doses of ara-C 2000 mg/m2, were ineligible,
but patients may have received less intensive postre m i s-
sion therapy before study entry.
Patients were classified by cytogenetics as “favorable” if
they had t(15,17), t(8,21), or inv16q. Patients with unequivo-
cal French-American-British (FAB) M3 morphology, without
cytogenetics perf o rmed, were also classified as favorable.
Patients were classified as poor risk if they had monosomy of
c h romosomes 5 or 7, abnormal 7q, or complex abnorm a l i t i e s .
Other patients were classified as intermediate risk, including
those with normal cytogenetics, +8, 11q23 abnorm a l i t i e s ,
miscellaneous abnormalities, and unknown cytogenetics.
Step 1: Consolidation Chemotherapy
Patients were treated with ara-C 2000 mg/m2 i n t r a-
venously over 2 hours, every 12 hours × 8 doses on days 1-4
plus etoposide 40 mg/kg by continuous intravenous (IV)
infusion over 96 hours on days 1-4. All chemotherapy calcu-
lations were based on corrected weight, defined as ideal
weight plus 25% of the difference between actual and ideal
weight. Granulocyte colony-stimulating factor (G-CSF)
5 mg/kg subcutaneously daily was started on day 14 of ther-
apy and continued until peripheral blood stem cell collec-
tion was completed. The dose of G-CSF could be escalated
to 10 mg/kg if stem cell collection was proceeding slowly. 
Stem Cell Collection
I n i t i a l l y, stem cell collection was begun when the white
blood cell (WBC) counts were >5 0 0 0 /µL. This pro c e d u re
was modified in August 1994 to begin collection at WBC
counts >1 0 , 0 0 0 /µL because of inefficient collections at
lower WBC counts. At the beginning of this study, not all
centers had the capability of measuring CD34+ c e l l s .
T h e re f o re, the target for stem cell collection was initially
either a CD34+ cell dose ≥10 × 1 06/kg or a mononuclear
cell count (MNC) ≥15 × 1 08/kg. By June 1995, the MNC
t a rget was reduced to 12 × 1 08/kg. By November 1995, all
centers had the capability of measuring CD34+ cells, and
the collection target was a CD34+ cell dose ≥10 × 1 06/kg. In
November 1996, the CD34+ cell dose target was reduced to
≥5 × 1 06/ k g .
L e u k o p h e resis was perf o rmed according to institutional
criteria, with processing of 12-18 L of blood daily. A buff y
coat was pre p a red by centrifugation and mixed in M199
media with 5% autologous plasma and 10% dimethyl sulfox-
ide to achieve a final cell concentration of 2.5 × 1 08 cells/mL.
The stem cell product was frozen in a contro l l e d - r a t e
freezer and stored in the liquid phase of liquid nitrogen.
C D 3 4+ and colony-forming unit granulocyte-macro-
phage (CFU-GM) assays were done according to institu-
tional criteria. During the first 18 months of the study,
patients had backup bone marrow collected after the com-
pletion of stem cell collection. 
Step 2: Autologous Stem Cell T r a n s p l a n t a t i o n
Patients were eligible to proceed to step 2 when they had
been out of the hospital for at least 4 weeks after completion
of consolidation chemotherapy and were documented to be
in continuous remission. This determination was made by
bone marrow biopsies perf o rmed within 2 weeks of admis-
sion and by peripheral blood counts with ANC ≥5 0 0 /µL and
platelets ≥5 0 , 0 0 0 /µL (either improving or stable).
The preparative regimen consisted of busulfan 1 mg/kg
orally every 6 hours for 16 doses (total dose 16 mg/kg)
on days –7 through –4, followed by intravenous etoposide
60 mg/kg over 10 hours on day –3. As in step 1, all chemo-
therapy doses were calculated according to corre c t e d
weight. Peripheral blood stem cells were infused on day 0.
Administration of G-CSF 5 mg/kg subcutaneously daily was
s t a rted on day 0 and continued until the ANC measure d
≥1500/µL for 2 consecutive days or >5000/µL for 1 day.
S u p p o rt i v e Care
During consolidation chemotherapy, patients re c e i v e d
fluorometholone ophthalmic solution 0.1% 2 drops 4 times
daily on days 1-6. Amphotericin 0.3 mg/kg per day was
started on day 5 and continued until ANC ≥500/µL.
During autologous stem cell transplantation, ampho-
tericin 0.3 mg/kg per day was started when ANC ,5 0 0 /µL
and continued until ANC ≥5 0 0 /µL. Acyclovir 2 mg/kg
intravenously every 12 hours was started on day –2 and
continued until it could be switched to acyclovir 200 mg
orally 3 times daily. This was continued for the first year
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after transplantation. Pneumocystis carinii p rophylaxis was
m a i ntained with trimethoprim-sulfamethoxazole 160 mg
2 times daily twice per week until at least 3 months after
transplantation or until CD4+ lymphocyte count ≥2 0 0 /µL .
Red blood cell (RBC) and platelet transfusions were admin-
istered according to institutional criteria.
To x i c i t y
Toxicity was graded according to the University of Cali-
f o rnia, San Francisco BMT Toxicity Grading Scale. Mucositis
was scored as grade 2 (moderate) if the patient re q u i red nar-
cotic analgesics or was unable to eat because of mucositis and
grade 3 (severe) if >25% of the mucosa was ulcerated. Skin
toxicity was scored as grade 2 (moderate) if the patient
re q u i red narcotic analgesia or local care (or both) and grade 3
( s e v e re) if significant desquamation and breakdown occurre d .
Statistical Evaluation
DFS was calculated from the date of the start of step 1
consolidation chemotherapy using Kaplan-Meier analysis
on a Macintosh computer. Data were analyzed as of
F e b ru a ry 9, 1999.
RESULTS
A total of 128 patients were treated (Table 1). Patients
w e re enrolled at the University of California, San Francisco
(n = 65), St. Joseph’s Medical Center (n = 20), Maine Medical
Center (n = 18), Hahnemann Medical Center (n = 18), State
University of New York, Syracuse (n = 8), and Alta Bates
Medical Center (n = 3). Thirty-six patients (28%) were over
50 years of age, 5 patients (4%) were over 60 years, and
median age was 39 years. The median WBC count at diagno-
sis was 9000/µL, and 15 patients (12%) had WBC counts
g reater than 100,000/µL. Eighty-eight patients (69%)
received induction chemotherapy with high-dose ara-C
(HDAC) and daunorubicin. Thirty-two patients re c e i v e d
s t a n d a rd-dose ara-C plus anthracycline therapy, and 8 p a t i e n t s
received all-t r a n s retinoic acid (ATRA) plus idarubicin or
d a u n o rubicin. One hundred nineteen patients (93%) re c e i v e d
no postremission therapy before study entry. Nine patients
received some prior postremission therapy, 7 with a single
course of standard-dose ara-C–based regimen and 2 with
2 -day regimens of HDAC. The median interval between
achieving remission and study entry was 42 days, and
9 patients were enrolled after intervals longer than 100 days.
T h i rty-eight patients were classified as favorable;
22 patients had acute promyelocytic leukemia FAB M3. In
19 patients, t(15,17) was demonstrated. One patient did not
have a cytogenetics assay, and in 2 patients cytogenetics
assays were re p o rtedly normal. Eight of the 22 patients
had WBC counts >5 0 0 0 /µL, and 2 had WBC counts
>1 0 0 , 0 0 0 /µL. Eight patients had FAB M4Eo, and all of
these had inv16q. One of these patients had a WBC count
>1 0 0 , 0 0 0 /µL. Eight patients had t(8,21). The median age
for all favorable patients was 36 years.
Seven patients (median age 46) had poor-risk feature s :
1 patient had –7, 1 had –5, 1 patient had complex abnormal-
ities including –7, 3 patients had both –7 and –5, and
1 patient had an abnormal 7q+.
Eighty three patients were classified as interm e d i a t e
risk. Fifty-four patients had normal cytogenetics, 3 patients
had 11q23 abnormalities including 2 patients with t(9,11),
4 patients had +8, 8 patients had miscellaneous a b n o rm a li-
ties, and cytogenetics assays were not perf o rmed in 14 p a t i e n t s .
The intermediate-risk patients included 3 patients with
FAB M6 and 2 with FAB M0. 
Step 1: Consolidation Chemotherapy
Consolidation chemotherapy was generally well toler-
ated. Hematologic toxicity was as expected, with a median of
13 days with ANC ,500/µL (Table 2). Patients required a
median of 4 (range 0-19) units of RBCs and 6 (range 1-34)
platelet transfusions. There was little nonhematologic toxic-
ity, with median 0 (range 0-22) days of parenteral nutrition
and 0 (range 0-24) days of narcotic agents (Table 3). Four-
teen patients (11%) re q u i red more than 14 days of par-
enteral nutrition, and 14 patients received more than
14 days of parenteral narcotics. The median number of days
with mucositis ≥grade 2 was 0 (range 0-10), but 4 patients
had mucositis ≥grade 2 lasting more than 7 days. No patient
had significant skin toxicity. Two patients experienced tran-
sient central nervous system neurotoxicity related to
HDAC, but recovered completely. There was little hepato-
t o x i c i t y, with a median bilirubin of 1.0 mg/dL (range 0.5-
6.6). Seven patients had a peak bilirubin >3 mg/dL, and the
highest bilirubin was 6.6 mg/dL. The 1 tre a t m e n t - re l a t e d
death was due to sepsis. Ten patients suffered relapse after
completing consolidation and before transplantation.
Table 1. Patient Features*
Median
Age (years) 39 (range 18-65)





Not done 14 (11%)
*WBC indicates white blood cells.
Table 2. Hematologic Recovery*
Median Values (Range)
Step 1 Step 2
ANC/ µL >100 20 (15-28) +8 (5-15)
>500 21 (17-29) +9 (7-15)
>1000 21 (17-32) +9 (7-15)
Days ANC <500/ µL 13 (7-27) 5 (3-14)
Platelets / µL >20,000 24 (16-27) +13 (0-359)
>50,000 28 (18-72) +19 (8-400 +)
>100,000 35 (18-400 +) +28 (9-400 +)
Platelet Tx 6 (1-34) 3 (0-100)
RBC units 4 (0-19) 3 (0-20)
*ANC indicates absolute neutrophil count; RBC, red blood cell; Tx,
transplantation.
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Stem Cell Collection
The median day to first stem cell collection was day 25
(range 18-40) of treatment (Table 4). Patients underwent a
median of 3 (range 1-11) collections. However, the targ e t
for stem cell collection evolved over time as institutions
developed the capacity to measure CD34+ cells. We initially
set a very high CD34+ target of 10 × 106/kg. This decision
was based on previous ABMT data that demonstrated that
engraftment in AML patients was slower than that in
patients with other diseases. As we developed more experi-
ence with this regimen, the CD34+ cell dose target was
reduced to 5 × 106/kg. 
If the stem cell collection results are analyzed based on a
C D 3 4+ t a rget cell dose of 5 × 1 06/kg, 57% (ie, 55/96 for
whom CD34+ data are available) achieved this goal in 1 col-
lection. The mean number of collections to reach the target
was 1.9 (range 1-9); collections were obtained from 89% of
patients in ≤3 days, and only 2 patients required >5 days. 
Patients with successful collections numbered 126 of
127. One patient who failed to mobilize during the period
of sepsis subsequently had stem cells mobilized with G-CSF
alone and then proceeded to transplantation.
Step 2: Autologous Stem Cell T r a n s p l a n t a t i o n
Of 128 patients, 117 (91%) proceeded to transplanta-
tion. No patient was precluded from proceeding to trans-
plantation because of toxicity.
Engraftment after stem cell infusion was rapid, with
ANC >500 by day +9 and with no patients reaching this
landmark later than day +15 (Table 2). Median number of
days spent with ANC ,500 was 5 (range 3-14). Platelets
re c o v e red to >2 0 , 0 0 0 /µL by day +13. Only 12 patients
required more than 30 days to reach this landmark, and only
2 patients re q u i red more than 100 days. One of these
patients never engrafted platelets and died of sepsis on
day +359, probably because of his continued use of an
indwelling catheter. The median number of transfusions
re q u i red was 3 units of RBCs (range 0-20, mean 3.6) and 3
platelet transfusions (range 0-100, mean 5.2). No patient
was infused with backup pelvic bone marrow.
The incidence of nonhematologic toxicity of the re g i-
men was very acceptable (Table 3). Median number of days
of parenteral nutrition were 6 (range 0-34), and median days
of narcotic analgesia 7 (range 0-27). Some outliers i n c l u d e d
8 patients (7%) receiving more than 3 weeks of p a re n t e r a l
nutrition and 2 patients receiving more than 3 weeks of nar-
cotic agents. Median number of days with mucositis ≥grade 2
was 6 (range 0-16), and only 1 patient had this degree of
mucositis for longer than 14 days. Skin toxicity was minimal
with median 0 (range 0-16) days of grade 2 toxicity; only 1
patient had more than 14 days of grade 2 toxicity. No patient
had more than 2 days of grade 3 skin toxicity.
There was little hepatotoxicity, with median peak biliru-
bin of 0.9 mg/dL (range 0.4-3.6). Patients were discharged
f rom the hospital by median day +15 (range 9-59). Only 6
patients were hospitalized longer than 30 days and only 1
patient longer than 40 days after stem cell infusion.
T h e re were 2 tre a t m e n t - related deaths. One was an
i a t rogenic death related to perforation of the duodenum
during endoscopy, with resulting acute re s p i r a t o ry distre s s
s y n d rome. The other patient, who retained a central
catheter (mentioned above) because of failure to engraft
platelets, died of sepsis 1 year after transplantation.
Treatment Outcome
A total of 128 patients began the study therapy (Table 5).
During consolidation chemotherapy, there was 1 death fol-
lowed by 10 early relapses. One hundred seventeen patients
p roceeded to transplantation. During transplantation, 2 tre a t-
m e n t - related deaths occurred, and 35 relapses occurred after
transplantation. Median time to relapse was 9.0 months
(range 5.5-35), and median time to relapse after transplanta-
tion was 7.0 months (range 3.0-32.5) for transplanted
patients. With median follow-up of 30 months (range 2-66),
5-year DFS is 55% (95% confidence interval 45%-65%)
( F i g u re 1). There was a nonsignificant trend toward impro v e d
outcome for patients aged <40 compared with those ≥40, with
DFS 61% ± 7% versus 49% ± 7%, re s p e c t i v e l y. The small
g roup of patients aged >60 tolerated therapy well, with 3 of 5
remaining in remission (relapse in 1 patient with FAB M6 and
n o rmal cytogenetics pro file and in 1 patient with poor- r i s k
cytogenetics). There was also a nonsignificant trend toward
i m p roved outcome for those who received HDAC induction
c o m p a red with those who received standard-dose induction
therapy (DFS 66% versus 50%).
For 38 favorable-risk patients, overall 5-year DFS is
73% (range 58%-88%) (Figure 2). Five-year DFS for the 22
patients with FAB M3 is 71% and is not significantly differ-
ent for those with WBC counts above or below 5000/µL
(71% versus 73%). However, both M3 patients with WBC
counts >1 0 0 , 0 0 0 /µL suff e red relapses. Those 8 FAB M3
patients who received ATRA-containing induction therapy
Table 3. Nonhematologic Toxicity* 
Median Values (Range)
Step 1 Step 2
Days on TPN 0 (0-2) 6 (0-34)
Days on narcotic agents 0 (0-2) 7 (0-27)
Hospital discharge 25 (18-73) +15 (9-59)
Peak bilirubin (mg/dL) 1.0 (0.5-6.6) 0.9 (0.4-3.6)
*TPN indicates total parenteral nutrition.
Table 4. Stem Cell Collection* 
Median Values (Range)
Start day 25 (18-40)
Collection (n) 3 (1-11)
Collection (n) to CD34 + >5 (×10 6/kg) 1 (1-9)
MNC ( ×10 8/kg) 11 (0.5-57)
CD34 + (×10 6/kg) 14.6 (1.8-230)
CFU-GM ( ×10 4/kg) 193 (1.5-2100)
*CFU-GM indicates colony-forming unit granulocyte-macrophage; MNC,
mononuclear leukocytes.
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had a trend toward improved outcome, with DFS 88% ver-
sus 64%. The 5-year DFS for 8 patients with FAB M4Eo is
83%, with 1 death and no relapses. The 5-year DFS for
8 patients with t(8,21) is 69%, with 2 relapses. All 7 patients
with poor-risk cytogenetics relapsed either before or within
1 year of transplantation.
For the 83 patients with intermediate-risk disease,
o v e rall 5-year DFS is 51% (range 38%-64%). No signific a n t
d i ff e rence in outcome exists between patients with norm a l
cytogenetics (DFS 48%) and those whose cytogenetics were
not obtained (DFS 62%). There is no diff e rence in outcome
for intermediate-risk patients based on induction chemo-
therapy received. Of the 57 patients who received HDAC
induction, 20 suff e red relapse and DFS is 52%. Of the
26 patients who received standard induction, 13 suff e re d
relapse and DFS is 48%. Among the interm e d i a t e - r i s k
patients, there is a trend toward better outcome in those
under age 40, with DFS 61% versus 40% for those over age
40. Two of 4 patients with +8 and 3 of 3 patients with 11q23
a b n o rmalities remain well. One of 3 patients with FAB M6
and 0 of 2 patients with FAB M0 remain in remission. High
WBC count by itself does not appear to be an adverse prog-
nostic factor. Of the 12 intermediate-risk patients with
WBC ≥1 0 0 , 0 0 0 /µL, 1 death and 2 relapses occurred with
5 -year DFS of 72%.
DISCUSSION
For any treatment strategy to be successful, patients
should be able to receive all of the intended treatment. By
this criterion, our 2-step approach to autologous stem cell
transplantation for AML is highly effective, with 91% of
the patients able to receive the intended therapy. Of the
1 2 8 patients, only 1 patient died during step 1, and no
patient was prevented from proceeding to transplantation
because of toxicity. Ten early relapses occurred; such
relapses will be unavoidable if patients are enrolled in the
study rapidly after achieving remission. Four of these 10 early
relapses were in patients with high-risk cytogenetics. Of
favorable-risk and intermediate-risk patients, 94% received
the full intended therapy. Intensive-induction chemotherapy
(HDAC plus daunorubicin) in the majority of these patients
possibly contributed to their ability to remain in remission
long enough to receive the planned treatment.
This consolidation-chemotherapy regimen of HDAC
plus etoposide appears to be highly effective in mobilizing
peripheral blood stem cells. Only 1 of 127 patients had an
inadequate stem cell collection, and this appeared to be
related to ongoing sepsis. The median number of collec-
tions to reach a CD34+ cell dose target ≥5 × 1 06/kg is 1,
with 93% reaching this target in ≤3 days. Engraftment of
Table 5. Outcome
All Favorable Intermediate Poor
Step 1 128 38 83 7
Death 1 0 1 0
Early relapse 10 1 5 4
Step 2 117 37 77 3
Death 2 1 1 0
Relapse 35 7 25 3
Continuing remission 80 29 51 0
Figure 1. Disease-free survival (DFS) of all 128 patients entered in study. Error bars indicate 95% confidence intervals.
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these peripheral blood stem cells was extremely rapid. Neu-
t rophils >500 were reached by day +9, and no patients
engrafted neutrophils later than +15. The total number of
days spent neutropenic (ANC ,500) was 5. This short
duration of neutropenia likely contributed to the low tre a t-
m e n t - related mortality and low morbidity. Platelets re c o v-
e red to >2 0 , 0 0 0 /µL by day +13, and only 2 patients re a c h e d
this point later than day +100. Transfusion re q u i re m e n t s
w e re low, with patients requiring a median of 3 units of
RBCs and 3 platelet transfusions.
The toxicity level of the transplantation step was very
acceptable and appeared markedly different from our expe-
rience with the identical regimen when 4HC-purged bone
m a rrow was used. The median number of days re q u i r i n g
parenteral nutrition fell from 38 to 6, and the median num-
ber of days requiring parenteral narcotics fell from 19 to 7.
Rapid neutrophil re c o v e ry likely contributed to re d u c e d
g a s t rointestinal toxicity. Less easy to understand is the
marked decrease in skin toxicity, which was one of the seri-
ous problems with our prior regimen. Pre v i o u s l y, 20% of
patients had severe skin toxicity lasting longer than 14 days,
w h e reas no patient in the current study experienced this
level of toxicity. In terms of re s o u rce utilization, the use
(median during both treatment steps) of 7 units of RBCs
and 9 platelet transfusions is less than the 11 units of blood
and 23 platelet transfusions re q u i red during ABMT sup-
ported by 4HC-purged bone marrow. The total number of
days of hospitalization was similar, 48 days (2-step stem cell)
versus 49 days (purged-bone marrow). 
I m p roved treatments are needed for patients with
AML. HDAC has been demonstrated to be superior to
s t a n d a rd-dose ara-C, but for most patients with interm e d i-
ate-risk disease, DFS is only 30% [5-7]. No additional
agents are currently available, and there are no modifica-
tions of HDAC regimens that appear to produce superior
results. On the other hand, ablative therapy with allogeneic
BMT has been clearly demonstrated to reduce relapse rates
in patients with fir s t - remission AML [8]. Some of the eff e c-
tiveness of allogeneic BMT is related to the graft-versus-
leukemia effect, but the preparative regimen also appears to
have a role. More intensive preparative regimens have been
shown to significantly reduce the relapse rate, suggesting
that the regimen is important [9]. T-cell depletion does not
markedly increase the relapse rate in AML patients (in con-
trast to that in CML patients), and, re c e n t l y, excellent
results have been obtained with T-cell-depleted allogeneic
B M T. This finding suggests that the ablative regimen is the
critical factor in reducing relapse [10].
Autologous transplantation has been pursued as a
p o s t remission therapy for AML based on the hope that the
ablative regimen would reduce relapse and lead to
i m p roved outcomes. However, the role of ABMT in the
management of first-remission AML remains undefined at
this time. Two large phase III studies have been re p o rt e d
with somewhat conflicting results [5,11]. A large Euro p e a n
study [11] demonstrated an improvement in DFS fro m
A B M T, whereas an American study [5] did not. However,
both studies were plagued by the fact that a low perc e n t a g e
of patients received the intended therapy. In the Euro-
pean study, only 68% of remission patients reached the
point of randomization/allocation, and, of patients ran-
domized to receive ABMT, only 74% did so. In the Amer-
ican study, a similar pattern was observed, with only 67% o f
remission patients reaching randomization/allocation and
with only 54% of patients randomized to ABMT re c e i v i n g
the transplant.
It is difficult to know all the factors that led to such a
high dropout rate in the ABMT arm, but lack of physician
F i g u r e 2. Disease-free survival of all patients entered in study according to cytogenetic risk group: 38 favorable, 83 intermediate, and 7 poor. Error bars indicate
95% confidence intervals.
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enthusiasm was a possible contributing factor. The influence
on ultimate outcome of the intensity of chemotherapy given
before ABMT is unknown, but the absence of any interme-
diate- or high-dose ara-C in the American study may have
contributed to the suboptimal result in the autograft arm.
It is not the purpose of the current study to compare out-
comes to other forms of therapy, but several observations can
be made. For fir s t - remission patients with favorable cytoge-
netic subtypes of AML, several treatment options can re s u l t
in >50% likelihood of prolonged DFS. Patients with FAB M3
and WBC counts ,1 0 , 0 0 0 /µL have 4-year DFS >7 0 % ,
w h e reas those with higher WBC counts do more poorly
(DFS <40%) [12-14]. Patients with t(8,21) have pro l o n g e d
DFS of 50% to 70% [7,15-17], and those with inv16q have
DFS of 40% to 60% [7,15-17]. Although ABMT may not be
n e c e s s a ry as a first treatment option in this favorable group of
patients, the outcome appears to be at least as good, with no
s i g n i ficant increase in treatment mort a l i t y. It should be noted
that most of the FAB M3 patients in this trial never re c e i v e d
ATRA and that favorable outcomes were not limited to those
with low WBC count. Further understanding of pro g n o s t i c
factors in patients with promyelocytic leukemia may help us
to better select those patients who will fare best with ablative
therapy as the initial approach. Our patients with FAB M4Eo
f a red very well, with no relapses in 8 patients, suggesting that
initial ABMT may be a valid appro a c h .
Patients with poor-risk cytogenetics have fared poorly
with most forms of therapy. Allogeneic transplantation
appears to be the treatment of choice for those younger
patients with a matched sibling donor, but even with these
the cure rate is only 25% [18-21]. None of the 7 patients
with –7/–5 in this trial remained in remission, and i m p ro v e d
a p p roaches are needed.
For the large group of patients with interm e d i a t e - r i s k
AML, the projected DFS of 51% compares favorably with
the 30% DFS reported after HDAC postremission therapy.
Neither WBC count ≥1 0 0 , 0 0 0 /µL nor age ≥40 years was
detrimental to this outcome. 
Autologous stem cell transplantation remains a promis-
ing therapy in the management of AML [22-27]. The 2-step
approach outlined here allows a high percentage of patients
to remain in remission, yield adequate doses of stem cells
that can engraft rapidly, and proceed to transplantation. In
the setting of rapid engraftment, patients can tolerate very
intensive preparative regimens with little mortality and very
acceptable morbidity. This reduction in toxicity has allowed
us to safely extend age eligibility into the seventh decade.
Recent data suggest that posttransplantation immunother-
apy may be able to further reduce relapse rates and that
additional studies are warranted [28].
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